Merck Reports the Initiation of Rolling Submission to Health Canada for Molnupiravir to Treat COVID-19

 Merck Reports the Initiation of Rolling Submission to Health Canada for Molnupiravir to Treat COVID-19

Shots:

  • The initiation of a rolling submission to Health Canada for molnupiravir (bid, for 5 days) to treat COVID-19 is based on the P-II interim results from the P-II/III MOVe-OUT clinical trials. The therapy is being developed in collaboration with Ridgeback
  • The submission was accepted under the Minister of Health’s interim order and enables the review of early safety, quality and efficacy data while later-stage clinical trials are ongoing
  • The therapy is being currently evaluated in P-III MOVe-OUT clinical trials trial in 1550 non-hospitalized adults in a ratio (1:1) with SARS-CoV-2 with at least one risk factor associated with poor disease outcomes

Click here to­ read full press release/ article | Ref: Newswire.ca | Image: Shutterstock

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post